ロード中...
Tolvaptan, hyponatremia, and heart failure
Tolvaptan is the first FDA-approved oral V(2) receptor antagonist for the treatment of euvolemic and hypervolemic hyponatremia, in patients with conditions associated with free water excess such as heart failure, cirrhosis, and the syndrome of inappropriate antidiuretic hormone secretion. Tolvaptan...
保存先:
| 主要な著者: | , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Dove Medical Press
2011
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3108793/ https://ncbi.nlm.nih.gov/pubmed/21694950 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/IJNRD.S7032 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|